[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100127687":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":69,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Hadassah Medical Organization","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cancer patients",null,"women 5-45 yr olf pre and post chemotherapy",[13],"Biological: blood tests",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BIOLOGICAL","blood tests","time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Ariel Revel, MD","CONTACT","97226776424","arielr2@hadassah.org.il",[27],{"facility":28,"status":29,"city":30,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Hadassah","RECRUITING","Jerusalem","Israel","IL",{"type":34,"coordinates":35},"Point",[36,37],35.21633,31.76904,{"lat":37,"lon":36},[40,41],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":22,"role":42,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":10,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":22,"oldOrganization":28},"100127687","anti-mullerian-hormone-amh-and-antral-follicle-count-as-markers-of-ovarian-reserve--prospective-followup-of-young-cancer-patients-100127687",false,"NCT00930501","Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients","Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients","Ovrescancer","Inclusion Criteria:\n\n* all females prior and after chemotherapy\n\nExclusion Criteria:\n\n* do not consent","FEMALE","5 Years","45 Years",{"count":56,"type":57},100,"ESTIMATED","OBSERVATIONAL","young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.",[61],"Infertility",[63,64,65,66,67,68],"chemotherapy","cancer","AMH","gonadotoxicity","ovarian reserve","patients exposed to chemotherapy","UNKNOWN","2009-06-29",{"date":72,"type":57},"2009-06-30",{"date":74,"type":10},"2009-06",{"date":76,"type":57},"2013-12",{"name":5,"class":6},1]